Literature DB >> 11981733

Prevention of yellow fever in persons traveling to the tropics.

Thomas P Monath1, Martin S Cetron.   

Abstract

Yellow fever (YF) is a potentially lethal mosquito-borne viral hemorrhagic fever endemic in Africa and South America. Nine million tourists annually arrive in countries where YF is endemic, and fatal cases of YF have occurred recently in travelers. In this article, we review the risk factors for YF during travel and the use of YF 17D vaccine to prevent the disease. Although the vaccine is highly effective and has a long history of safe use, the occurrence of rare, fatal adverse events has raised new concerns. These events should not deter travelers to areas where YF is endemic from being immunized, because the risk of YF infection and illness may be high in rural areas and cannot be easily defined by existing surveillance. To avoid unnecessary vaccination, physicians should vaccinate persons at risk on the basis of knowledge of the epidemiology of the disease, reports of epidemic activity, season, and the likelihood of exposure to vector mosquitoes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11981733     DOI: 10.1086/340104

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  19 in total

1.  Yellow Fever Immunizations: Indications and Risks.

Authors:  Mary E. Wilson; Lin H. Chen; Elizabeth D. Barnett
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

2.  Yellow fever: readily prevented but difficult to treat.

Authors:  Erica Weir; Shariq Haider
Journal:  CMAJ       Date:  2004-06-22       Impact factor: 8.262

Review 3.  A review of the invasive mosquitoes in Europe: ecology, public health risks, and control options.

Authors:  Jolyon M Medlock; Kayleigh M Hansford; Francis Schaffner; Veerle Versteirt; Guy Hendrickx; Herve Zeller; Wim Van Bortel
Journal:  Vector Borne Zoonotic Dis       Date:  2012-04-20       Impact factor: 2.133

4.  Yellow fever vaccine seroconversion in travelers.

Authors:  Allison Kay; Lin H Chen; Maggie Sisti; Thomas P Monath
Journal:  Am J Trop Med Hyg       Date:  2011-10       Impact factor: 2.345

5.  A case of yellow fever vaccine-associated viscerotropic disease in Ecuador.

Authors:  Richard W Douce; Diana Freire; Betzabe Tello; Gavino A Vásquez
Journal:  Am J Trop Med Hyg       Date:  2010-04       Impact factor: 2.345

6.  Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization?

Authors:  M A Martins; M L Silva; A P V Marciano; V Peruhype-Magalhães; S M Eloi-Santos; j G L Ribeiro; R Correa-Oliveira; A Homma; E G Kroon; A Teixeira-Carvalho; O A Martins-Filho
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

7.  Statement on Older Travellers: Committee to Advise on Tropical Medicine and Travel.

Authors:  K L McClean
Journal:  Can Commun Dis Rep       Date:  2011-07-21

Review 8.  Yellow Fever Virus: Diagnostics for a Persistent Arboviral Threat.

Authors:  Jesse J Waggoner; Alejandra Rojas; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2018-09-25       Impact factor: 5.948

9.  President's address: travel medicine and principles of safe travel.

Authors:  Herbert L DuPont
Journal:  Trans Am Clin Climatol Assoc       Date:  2008

10.  Current Assessment of Yellow Fever and Yellow Fever Vaccine.

Authors:  Anabelle Lefeuvre; Philippe Marianneau; Vincent Deubel
Journal:  Curr Infect Dis Rep       Date:  2004-04       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.